UroGen Pharma (LTS:0XOD) Marketable Securities: $28.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0XOD UroGen Pharma Ltd LTS:0XOD
54 GF Score
Price $47.41
GF Value $26.01
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is UroGen Pharma Marketable Securities?

UroGen Pharma LTS:0XOD +1.13% 54 Marketable Securities is $28.8 Mil as of Jun. 2026. GuruFocus rates LTS:0XOD with a GF Score™ of 54/100 and a GF Value™ of $26.01 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. UroGen Pharma's Marketable Securities for the quarter that ended in Jun. 2026 was $28.8 Mil.

UroGen Pharma's annual Marketable Securities increased from Dec. 2023 ($42.0 Mil) to Dec. 2024 ($64.7 Mil) but then declined from Dec. 2024 ($64.7 Mil) to Dec. 2025 ($9.7 Mil).

UroGen Pharma  (LTS:0XOD) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

UroGen Pharma Marketable Securities Related Terms

UroGen Pharma Marketable Securities Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma Marketable Securities Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.78 44.56 41.97 64.70 9.71

UroGen Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.05 36.99 9.71 30.31 28.84
LTS:0XOD
54GF Score
UroGen Pharma Ltd LTS:0XOD
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $28.8 Mil mean?
UroGen Pharma (LTS:0XOD) has a Marketable Securities of $28.8 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on UroGen Pharma and its competitors.
Is UroGen Pharma's Marketable Securities too high?
UroGen Pharma's current Marketable Securities is $28.8 Mil. Overall, UroGen Pharma has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Marketable Securities compare to PVLA and AUPH?
UroGen Pharma's Marketable Securities of $28.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current Marketable Securities is $28.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (LTS:0XOD) is currently considered Significantly Overvalued. The stock's GF Value™ is $26.01, compared to a current price of $47.41 — trading 82.3% above its estimated fair value. The current Marketable Securities is $28.8 Mil. UroGen Pharma's overall GF Score™ is 54/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For UroGen Pharma (LTS:0XOD), the current Marketable Securities is $28.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (LTS:0XOD) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of $47.41 is trading 82.3% above its estimated GF Value™ of $26.01. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for LTS:0XOD:

  • Marketable Securities: $28.8 Mil
  • GF Value™: $26.01 vs. price of $47.41 (82.3% above fair value)
  • GF Score™: 54/100 with 9 warning signs

No single metric tells the full story. See the LTS:0XOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UroGen Pharma Business Description

Other Exchanges URGN:USAUR8:Germany
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
54GF Score

Get the complete analysis for LTS:0XOD

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.41
Price
$26.01
GF Value